PROSTAGLANDIN ANALOG OR RHO KINASE INHIBITOR – WHICH ONE IS BETTER IN PRIMARY OPEN-ANGLE GLAUCOMA
DOI:
https://doi.org/10.22159/ajpcr.2023.v16i11.48337Keywords:
Key words – Bimatoprost, Ripasudil, Dry Eye, Hyperaemia, Primary Open Angle Glaucoma, Adverse effectAbstract
Objective: The aim of the study was to compare the efficacy, safety, and adverse drug reactions of ripasudil and bimatoprost.
Methods: An open-label, prospective, observational, randomized study was carried out in the Department of Pharmacology M.L.N. Medical College in association with Manohar Das Regional Institute of Ophthalmology, Prayagraj, for 1 year after ethical clearance. A total of 118 patients with primary open-angle glaucoma fulfilling the inclusion and exclusion criteria were taken and randomized into two groups. Only 109 patients completed the study, Group 1 received ripasudil (n=54) and Group 2 received bimatoprost (n=55). Intraocular pressure (IOP), ocular surface disease index (OSDI), tear brake-up time (TBUT), and hyperemia were measured at the initiation of treatment and then measured at different time intervals.
Results: Group 1 and Group 2 patients were observed and followed up for 3 months. At the end of the 2nd, 4th, 6th, and 12th week in Group 1, ripasudil significantly showed better results in reducing IOP as compared to Group 2 bimatoprost. In terms of TBUT, both groups at the 12th week did not show any significant difference. The OSDI score of both groups showed a non-significant difference at the 12th week. At the end of 2nd week, hyperemia was comparable for both groups but ripasudil showed more hyperemia at the end of the 12th week.
Conclusion: We concluded that ripasudil is more effective than bimatoprost in reducing IOP in patients with primary open-angle glaucoma. In terms of adverse effect profile, both drugs showed similar effects in TUBT and OSDI scores. The safety profile of both drugs is similar but the hyperemia score of ripasudil is more than bimatoprost.
Downloads
References
World Glaucoma Association. What is Glaucoma. Available from: https://wga.one [Last accessed on 2021 Apr 17].
Mansouri K, Weinreb RN. Ambulatory 24-h intraocular pressure monitoring in the management of glaucoma. Curr Opin Ophthalmol 2015;26:214-20. doi: 10.1097/ICU.0000000000000144, PMID 25784109
National Institute of Eye. Glaucoma: The “Silent Thief” Begins to Tell its Secrets. Available from: https://www.nei.nih.gov/about/ news-and-events/news/glaucoma-silent-thief-begins-tell-its-secrets#:~:text=glaucoma%20is%20sometimes%20called%20 the,there%20is%20any%20vision%20loss [Last accessed on 2021 May 10].
Kingman S. Glaucoma is second leading cause of blindness globally. Bull World Health Organ 2004;82:887-8. PMID 15640929
National Institute of Eye. At a Glance: Glaucoma. Available from: https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/glaucoma#:~:text=There’s%20no%20cure%20for%20 glaucoma,damage%20and%20protect%20your%20vision [Last accessed on 2021 May 14].
Senjam SS. Glaucoma blindness-a rapidly emerging non-communicable ocular disease in India: Addressing the issue with advocacy. J Fam Med Prim Care 2020;9:2200-6. doi: 10.4103/jfmpc.jfmpc_111_20, PMID 32754474
Ahmad A, Ahmad SZ, Khalique N, Ashraf M, Alvi Y. Prevalence and associated factor of glaucoma in Aligarh, India A population based study. Delhi J Ophthalmol 2020;1:36-40. doi: 10.7869/djo.565
Schmidl D, Schmetterer L, Garhöfer G, Popa-Cherecheanu A. Pharmacotherapy of glaucoma. J Ocul Pharmacol Ther 2015;31:63-77. doi: 10.1089/jop.2014.0067, PMID 25587905
Patil AJ, Vajaranant TS, Edward DP. Bimatoprost - a review. Expert Opin Pharmacother 2009;10:2759-68. doi: 10.1517/14656560903292649, PMID 19874254
Mandell KJ, Kudelka MR, Wirostko B. Rho kinase inhibitors for treatment of glaucoma. Expert Rev Ophthalmol 2011;6:611-22. doi: 10.1586/eop.11.65, PMID 30613208
Goel M, Picciani RG, Lee RK, Bhattacharya SK. Aqueous humour dynamics: A review. Open Ophthalmol J 2010;4:52-9. doi: 10.2174/1874364101004010052, PMID 21293732
Nakano K, Arai R, Mabuchi I. The small GTP binding protein Rho1 is a multifunctional protein that regulates actin localization, cell polarity, and septum formation in the fission yeast Schizosaccharomyces pombe. Genes Cells 1997;2:679-94. doi: 10.1046/j.1365-2443.1997.1540352.x, PMID 9491802
Woodward DF, Krauss AH, Chen J, Lai RK, Spada CS, Burk RM, et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol 2001;45:S337-45. doi: 10.1016/s0039-6257(01)00224-7, PMID 11434936
Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M, et al. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 2013;156:731-6. doi: 10.1016/j.ajo.2013.05.016, PMID 23831221
Wanichwecha RB, Iemsomboon W. Efficacy and safety of bimatoprost for the treatment of open-angle glaucoma and ocular hypertension: A three-month, open-label study in community-based practices in Thailand. J Med Assoc Thai 2005;88:1228-35. PMID 16536109
Lewis RA, Christie WC, Day DG, Craven ER, Walters T, Bejanian M, et al. Bimatoprost sustained-release implants for glaucoma therapy: 6-month results from a phase I/II clinical trial. Am J Ophthalmol 2017;175:137-47. doi: 10.1016/j.ajo.2016.11.020, PMID 28012819
Kusuhara S, Nakamura M. Ripasudil hydrochloride hydrate in the treatment of glaucoma: Safety, efficacy, and patient selection. Clin Ophthalmol 2020;14:1229-36.
Published
How to Cite
Issue
Section
Copyright (c) 2023 RICHA OJHA, DR. RAKESH CHANDRA CHAURASIYA, DR, JAGRITI RANA, DR. DWIVIDENDRA KUMAR NIM, DR. VIJAY KUMAR SINGH
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
